Micro- and macrovascular function in the highest city in the world: a cross sectional study.

Altitude Chronic mountain sickness Flow-mediated dilation Inflammation Microcirculation

Journal

Lancet regional health. Americas
ISSN: 2667-193X
Titre abrégé: Lancet Reg Health Am
Pays: England
ID NLM: 9918232503006676

Informations de publication

Date de publication:
Oct 2024
Historique:
received: 05 09 2023
revised: 04 07 2024
accepted: 29 08 2024
medline: 9 10 2024
pubmed: 9 10 2024
entrez: 9 10 2024
Statut: epublish

Résumé

Since vascular responses to hypoxia in both healthy high-altitude natives and chronic mountain sickness (a maladaptive high-altitude pathology characterised by excessive erythrocytosis and the presence of symptoms-CMS) remain unclear, the role of inflammation and oxidative/nitrosative stress on the endothelium- 94 men were included: 18 lowlanders (LL), 38 healthy highlanders permanently living at 3800 m (n = 21-HL-3800) or in La Rinconada, the highest city in the world (5100-5300 m) (n = 17-HL-5100/No CMS). Moreover, 14 participants with mild (Mild CMS) and 24 with moderate to severe CMS (Mod/Sev CMS) were recruited. All undertook two reactivity tests: i) local thermal hyperaemia (microcirculation) and ii) flow-mediated dilation (macrocirculation). Endothelium- Conductance and skin blood flow velocity during the microcirculation test, as well as macrocirculation progressively decreased with altitude (LL > HL-3800 > HL-5100/No CMS). CMS also induced a decrease in macrocirculation (HL-5100/No CMS > Mild CMS = Mod/Sev CMS), while glyceryl trinitrate restored vascular function. Both oxidative stress and nitric oxide metabolites increased with altitude only. Principal component analysis revealed that increasing inflammation with altitude was associated with a progressive decline in both micro- and macrovascular function in healthy highlanders. Both micro and macrovascular function are affected by chronic exposure to hypoxia, the latter being further compounded by CMS. The "Fonds de dotation AGIR pour les maladies chroniques", the "Air Liquide Foundation", and the "French National Research Agency".

Sections du résumé

Background UNASSIGNED
Since vascular responses to hypoxia in both healthy high-altitude natives and chronic mountain sickness (a maladaptive high-altitude pathology characterised by excessive erythrocytosis and the presence of symptoms-CMS) remain unclear, the role of inflammation and oxidative/nitrosative stress on the endothelium-
Methods UNASSIGNED
94 men were included: 18 lowlanders (LL), 38 healthy highlanders permanently living at 3800 m (n = 21-HL-3800) or in La Rinconada, the highest city in the world (5100-5300 m) (n = 17-HL-5100/No CMS). Moreover, 14 participants with mild (Mild CMS) and 24 with moderate to severe CMS (Mod/Sev CMS) were recruited. All undertook two reactivity tests: i) local thermal hyperaemia (microcirculation) and ii) flow-mediated dilation (macrocirculation). Endothelium-
Findings UNASSIGNED
Conductance and skin blood flow velocity during the microcirculation test, as well as macrocirculation progressively decreased with altitude (LL > HL-3800 > HL-5100/No CMS). CMS also induced a decrease in macrocirculation (HL-5100/No CMS > Mild CMS = Mod/Sev CMS), while glyceryl trinitrate restored vascular function. Both oxidative stress and nitric oxide metabolites increased with altitude only. Principal component analysis revealed that increasing inflammation with altitude was associated with a progressive decline in both micro- and macrovascular function in healthy highlanders.
Interpretation UNASSIGNED
Both micro and macrovascular function are affected by chronic exposure to hypoxia, the latter being further compounded by CMS.
Funding UNASSIGNED
The "Fonds de dotation AGIR pour les maladies chroniques", the "Air Liquide Foundation", and the "French National Research Agency".

Identifiants

pubmed: 39381083
doi: 10.1016/j.lana.2024.100887
pii: S2667-193X(24)00214-X
pmc: PMC11459627
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100887

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

None.

Auteurs

Yann Savina (Y)

HP2 laboratory, Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.

Aurélien P Pichon (AP)

Laboratory Mobility, Aging & Exercise (MOVE, EA6314), Faculty of Sport Sciences, University of Poitiers, Poitiers, France.

Lucas Lemaire (L)

HP2 laboratory, Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.

Connor A Howe (CA)

Centre for Heart, Lung, and Vascular Health, University of British Columbia, Kelowna, British Columbia, Canada.

Mathilde Ulliel-Roche (M)

HP2 laboratory, Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.
Grenoble Alpes University Hospital, Grenoble, France.

Sarah Skinner (S)

Interuniversity Laboratory of Human Movement Biology (LIBM, EA7424), "Red Blood cell and Vascular Biology" team, Univ Lyon - University Claude Bernard Lyon 1, Villeurbanne, France.
Laboratory of Excellence on Red Blood Cell (GR-Ex), Paris, France.

Elie Nader (E)

Interuniversity Laboratory of Human Movement Biology (LIBM, EA7424), "Red Blood cell and Vascular Biology" team, Univ Lyon - University Claude Bernard Lyon 1, Villeurbanne, France.
Laboratory of Excellence on Red Blood Cell (GR-Ex), Paris, France.

Nicolas Guillot (N)

Interuniversity Laboratory of Human Movement Biology (LIBM, EA7424), "Red Blood cell and Vascular Biology" team, Univ Lyon - University Claude Bernard Lyon 1, Villeurbanne, France.
Laboratory of Excellence on Red Blood Cell (GR-Ex), Paris, France.

Émeric Stauffer (É)

Interuniversity Laboratory of Human Movement Biology (LIBM, EA7424), "Red Blood cell and Vascular Biology" team, Univ Lyon - University Claude Bernard Lyon 1, Villeurbanne, France.
Laboratory of Excellence on Red Blood Cell (GR-Ex), Paris, France.

Matthieu Roustit (M)

HP2 laboratory, Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.
Grenoble Alpes University Hospital, Grenoble, France.

Ivan Hancco (I)

HP2 laboratory, Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.

Paul Robach (P)

HP2 laboratory, Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.
National School for Mountain Sports, Site of the National School for Skiing and Mountaineering (ENSA), Chamonix, France.

François Esteve (F)

HP2 laboratory, Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.

Vincent Pialoux (V)

Interuniversity Laboratory of Human Movement Biology (LIBM, EA7424), "Red Blood cell and Vascular Biology" team, Univ Lyon - University Claude Bernard Lyon 1, Villeurbanne, France.

Elisa Perger (E)

Istituto Auxologico Italiano, IRCCS, Sleep Disorders Center & Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital, Milan, Italy.
University of Milano-Bicocca, Milan, Italy.

Gianfranco Parati (G)

Istituto Auxologico Italiano, IRCCS, Sleep Disorders Center & Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital, Milan, Italy.
University of Milano-Bicocca, Milan, Italy.

Philip N Ainslie (PN)

Centre for Heart, Lung, and Vascular Health, University of British Columbia, Kelowna, British Columbia, Canada.

Stéphane Doutreleau (S)

HP2 laboratory, Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.
Grenoble Alpes University Hospital, Grenoble, France.

Philippe Connes (P)

Interuniversity Laboratory of Human Movement Biology (LIBM, EA7424), "Red Blood cell and Vascular Biology" team, Univ Lyon - University Claude Bernard Lyon 1, Villeurbanne, France.
Laboratory of Excellence on Red Blood Cell (GR-Ex), Paris, France.

Samuel Verges (S)

HP2 laboratory, Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.
Grenoble Alpes University Hospital, Grenoble, France.

Julien V Brugniaux (JV)

HP2 laboratory, Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.

Classifications MeSH